Physicochemical properties of ferumoxytol, a new intravenous iron preparation

被引:123
作者
Balakrishnan, V. S. [1 ]
Rao, M. [1 ]
Kausz, A. T. [1 ,2 ]
Brenner, L. [2 ,3 ]
Pereira, B. J. G. [2 ]
Frigo, T. B. [2 ]
Lewis, J. M. [2 ]
机构
[1] Tufts Med Ctr, Div Nephrol, Boston, MA 02111 USA
[2] AMAG Pharmaceut Inc, Cambridge, MA USA
[3] Brigham & Womens Hosp, Boston, MA 02115 USA
关键词
Bleomycin detectable iron; free iron; molecular weight; osmolality; ferumoxytol; POSITRON-EMISSION-TOMOGRAPHY; BLEOMYCIN-DETECTABLE IRON; RED-CELL UTILIZATION; HEMODIALYSIS-PATIENTS; FERRIC GLUCONATE; OXIDATIVE STRESS; ANEMIC PATIENTS; LABILE IRON; FORMULATIONS; PHARMACOKINETICS;
D O I
10.1111/j.1365-2362.2009.02130.x
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Intravenous iron is a critical component of anaemia management. However, currently available preparations have been associated with the release of free iron, a promoter of bacterial growth and oxidative stress. We determined the molecular weight, dialysability and capacity for free iron release of ferumoxytol, a semi-synthetic carbohydrate-coated superparamagnetic iron oxide nanoparticle. Ferumoxytol was compared with three intravenous iron preparations in clinical use: iron dextran (low molecular weight), sodium ferric gluconate and iron sucrose. Intravenous iron preparations were also incubated in rat, and pooled human sera (at concentrations of 600 mu M and 42 mu g mL(-1) respectively) from healthy subjects. The molecular weight of ferumoxytol was 731 kDa. The relative order of molecular weight was as follows: ferumoxytol > iron dextran > iron sucrose > sodium ferric gluconate. The least ultrafilterable iron was observed with ferumoxytol and the most with ferric gluconate. The least dialysable free iron was observed with ferumoxytol and the most with ferric gluconate. Incubation of intravenous iron preparations in rat or pooled human sera demonstrated minimal free iron release with ferumoxytol. The order of catalytic iron release as detected by the bleomycin detectable iron assay was as follows: ferumoxytol < iron dextran < iron sucrose < ferric gluconate. A similar trend was observed for the in vivo serum concentration of free iron in rats. In vitro observations from these experiments suggest that ferumoxytol has a favourable profile in terms of tendency to release free iron, in comparison with currently available intravenous iron preparations.
引用
收藏
页码:489 / 496
页数:8
相关论文
共 29 条
[1]
[Anonymous], 2006, Am J Kidney Dis, V47, pS1S145
[2]
Incidence of side-effects associated with high-dose ferric gluconate in patients with severe chronic renal failure [J].
Bastani, B ;
Jain, A ;
Pandurangan, G .
NEPHROLOGY, 2003, 8 (01) :8-10
[3]
Pharmacokinetics and red cell utilization of 52Fe/59Fe-labelled iron polymaltose in anaemic patients using positron emission tomography [J].
Beshara, S ;
Sörensen, J ;
Lubberink, M ;
Tolmachev, V ;
Långström, B ;
Antoni, G ;
Danielson, BG ;
Lundqvist, H .
BRITISH JOURNAL OF HAEMATOLOGY, 2003, 120 (05) :853-859
[4]
Pharmacokinetics and red cell utilization of iron(III) hydroxide-sucrose complex in anaemic patients:: a study using positron emission tomography [J].
Beshara, S ;
Lundqvist, H ;
Sundin, J ;
Lubberink, M ;
Tolmachev, V ;
Valind, S ;
Antoni, G ;
Långström, B ;
Danielson, BG .
BRITISH JOURNAL OF HAEMATOLOGY, 1999, 104 (02) :296-302
[5]
A simple, highly sensitive and improved method for the measurement of bleomycin-detectable iron: the 'catalytic iron index' and its value in the assessment of iron status in haemochromatosis [J].
Burkitt, MJ ;
Milne, L ;
Raafat, A .
CLINICAL SCIENCE, 2001, 100 (03) :239-247
[6]
Intravenous iron sucrose: Establishing a safe dose [J].
Chandler, G ;
Harchowal, J ;
Macdougall, IC .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2001, 38 (05) :988-991
[7]
Structure, chemistry, and pharmacokinetics of intravenous iron agents [J].
Danielson, BG .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2004, 15 (12) :S93-S98
[8]
Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease [J].
Drüeke, T ;
Witko-Sarsat, V ;
Massy, Z ;
Descamps-Latscha, B ;
Guerin, AP ;
Marchais, SJ ;
Gausson, V ;
London, GM .
CIRCULATION, 2002, 106 (17) :2212-2217
[9]
Labile iron in parenteral iron formulations and its potential for generating plasma nontransferrin-bound iron in dialysis patients [J].
Espósito, BP ;
Breuer, W ;
Slotki, I ;
Cabantchik, ZI .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2002, 32 :42-49
[10]
Sodium ferric gluconate complex in the treatment of iron deficiency for patients on dialysis [J].
Fishbane, S ;
Wagner, J .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2001, 37 (05) :879-883